Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma

International Journal of Pharmaceutics

Volumn 365, Issue 1-2, 2009, Pages 12-17

  Shrewsbury, Stephen B ^a   Bosco, Andrew P ^a   Uster, Paul S ^a  

^a MAP Pharmaceuticals Inc   (United States)

Author keywords

Budesonide; Nebulized; Pharmacokinetics; Safety

Indexed keywords

BUDESONIDE;

ABDOMINAL PAIN; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DYSMENORRHEA; EPISTAXIS; EYE IRRITATION; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFECTION; MAXIMUM PLASMA CONCENTRATION; MEDICAL NEBULIZER; NEBULIZATION; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SORE THROAT; THROMBOPHLEBITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ADULT; AREA UNDER CURVE; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; YOUNG ADULT;

EID: 57049157156     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.08.012     Document Type: Article

References (23)

1. Baker J.W., Mellon M., Wald J., Welch M., Cruz-Rivera M., and Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 103 (1999) 414-421
2. Banov C.H. The role of budesonide in adults and children with mild-to-moderate persistent asthma. J. Asthma 41 (2004) 5-17
3. Berger W.E., and Shapiro G.G. The use of inhaled corticosteroids for persistent asthma in infants and young children. Ann. Allergy Asthma Immunol. 92 (2004) 387-399
4. Berger W.E. Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs 65 (2005) 1973-1989
5. Bosco A.P., Armer T.A., and Uster P.S. A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization. Eur. Respir. J. 28 (2006) 712s
6. Bosco A.P., and Uster P.S. A novel submicron suspension formulation of nebulized budesonide significantly improves the fine particle dose and ultra-fine particle dose. J. Aerosol Med. 20 (2007) 171
7. Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., Smaldone G.C., and Guyatt G. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127 (2005) 335-371
8. Geller D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care 50 (2005) 1313-1321
9. Giraud V., and Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. 19 (2002) 246-251
10. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), 2006. Available from: http://www.ginasthma.org.
11. Kemp J.P., Skoner D.P., Szefler S.J., Walton-Bowen K., Cruz-Rivera M., and Smith J.A. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann. Allergy Asthma Immunol. 83 (1999) 231-239
12. Kofman, C., Berlinski, A., Zaragoza, S., 2004. Aerosol therapy for pediatric outpatients. RT: The Journal for Respiratory Care Practitioners. Available from http://www.rtmagazine. com/issues/articles/2004-03_05.asp (last accessed April 18, 2007).
13. Kraft W.K., Steiger B., Beussink D., Quiring J.N., Fitzgerald N., Greenberg H.E., and Waldman S.A. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J. Clin. Pharmacol. 44 (2004) 67-72
14. Luangvala M.M., Castillo M.C., and Bosco A.P. A novel submicron formulation of nebulized budesonide generates a significantly greater fine particle mass compared to a conventional budesonide suspension using an electronic micropump nebulizer. Am. J. Respir. Crit. Care Med. 177 (2008) A611
15. Luangvala M.M., Castillo M.C., and Bosco A.P. A novel submicron formulation of nebulized budesonide significantly improves delivery during the critical first minutes of nebulization using an electronic micropump nebulizer. Am. J. Respir. Crit. Care Med. 177 (2008) A610
16. McLaughlin T., Leibman M., Patel P., and Camargo C.A. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr. Med. Res. Opin. 23 (2007) 1319-1328
17. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J. Allergy Clin. Immunol. 120 (2007) S94-S138
18. O'Connell E.J. Optimizing inhaled corticosteroid therapy in children with chronic asthma. Pediatr. Pulmonol. 39 (2005) 74-83
19. Rau J.L. Practical problems with aerosol therapy in COPD. Respir. Care 51 (2006) 158-172
20. Rubin B.K. What does it mean when a patient says, "my asthma medication is not working?". Chest 126 (2004) 972-981
21. Schüepp K.G., Jauernig J., Janssens H.M., Tiddens H.A., Straub D.A., Stangl R., Keller M., and Wildhaber J.H. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J. Aerosol Med. 18 (2005) 225-235
22. Shapiro G., Mendelson L., Kraemer M.J., Cruz-Rivera M., Walton-Bowen K., and Smith J.A. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J. Allergy Clin. Immunol. 102 (1998) 789-796
23. Szefler S.J., and Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J. Allergy Clin. Immunol. 109 (2002) 730-742